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Abstract The osteopontin SVVYGLR motif binds the integrins
K4L1 and K9L1. We show that K4L7 also interacts with this motif
and that an SVVYGLR-OH peptide antagonises the K4L7
MAdCAM interaction. The important elements of this motif
required to bind K4L1 and K4L7 were probed using a series of
mutated peptides based around SVVYGLR. Leu167 is important
for the interaction with K4 integrins, as is the C-terminal
carboxylic acid of Arg168 exposed by thrombin cleavage. The
importance of the acidic group means that SVVYGLR has
structural elements in common with other K4 integrin-binding
motifs and suggests why thrombin cleavage activates this
motif. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The integrins comprise a large family of heterodimeric
transmembrane receptors that mediate both cell^cell and
cell^matrix interactions [1]. They engage numerous ligands
and regulate a variety of cellular and physiological processes
such as cell proliferation, apoptosis, migration, di¡erentiation,
in£ammation and tissue remodelling [2]. The integrins K4L1,
K4L7 and K9L1 form a subfamily of receptors based on se-
quence homology and ligand-binding repertoire [3]. They me-
diate the migration of leukocytes into, and maintain their
activation at sites of in£ammation [4^8]. Therefore antago-
nists of these integrins have potential as anti-in£ammatory
agents. Indeed blocking K4 integrins reduces the in£ammatory
in¢ltrate in a number of models of in£ammation, while block-
ade of K9L1 reduces neutrophil chemotaxis [8^14].
Osteopontin binds a number of integrins via two contigu-
ous but distinct motifs within the sequence GRGD-
SVVYGLR (amino acid residues 158^168). The integrins
KvL3, KvL1, KvL5, K8L1 and K5L1 bind via a classical RGD
motif [15^20], while K4L1 and K9L1 bind via the cryptic
SVVYGLR motif generated by thrombin cleavage at
Arg168 [21,22]. The SVVYGLR motif is unusual as it lacks
a critical acidic residue present in other binding motifs for
K4L1 and K9L1. For example K4L1 binds various Asp-contain-
ing motifs in ¢bronectin, namely connecting segment-1 (CS-1),
CS-5, ¢bronectin type three repeat (FN-III)5 and FN-III14, as
well as vascular cell adhesion molecule (VCAM) and the dis-
integrin EC3 [23^28]. Similarly K9L1 binds VCAM and tenas-
cin via Asp-containing motifs [8,29,30].
The third member of this integrin subfamily, K4L7, binds
VCAM, CS-1 and FN-III5, as well as the K4L7-speci¢c ligand
mucosal addressin cell adhesion molecule (MAdCAM). Again
these interactions are all dependent on a critical Asp residue
[24,28,31,32]. Given that K4L1 and K9L1 bind a number of
common ligands, including osteopontin, it was of interest to
determine whether K4L7 also bound osteopontin, and to de-
termine the residues in the SVVYGLR motif required to in-
teract with K4 integrins.
2. Materials and methods
2.1. Cell culture
RPMI8866 cells and Jurkat cells were maintained in 1:1 RPMI1640
HEPES modi¢cation (Gibco):DMEM HEPES modi¢cation (Sigma)
supplemented with Glutamax (Gibco) and 10% FCS.
2.2. Antibodies and other reagents
Antibody clones were as follows; anti-L1 integrin antibody (4B4)
(Coulter). Anti-K4 integrin (HP2/1), anti-K5 integrin (SAM-1), anti-Kv
integrin (69-6-5) (Immunotech). The anti-L7 integrin antibody
(Fib504) was puri¢ed in house. The synthetic peptides Ac-
SVVYGLR-OH (SVVYGLR-OH, parent), Ac-GRVLYSV-OH
(GRVLYSV-OH, scrambled control) and Ac-SVVYGLR-NH2
(SVVYGLR-NH2, capped) were synthesised at GlaxoSmithKline.
The series of peptides in which each residue of the SVVYGLR motif
was individually mutated to Ala were purchased from Cambridge
Research Biochemicals Ltd. (Stockton-on-Tees, UK).
2.3. Production of recombinant protein fragments
All glutathione S-transferase (GST) bacterial expression constructs
were as previously described [26]. The recombinant zz-VCAM and zz-
MAdCAM, comprising the extracellular domain of each molecule
coupled to the immunoglobulin-binding domain of protein-A, were
expressed in baculovirus and puri¢ed using an IgG-coupled a⁄nity
column.
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2.4. Adhesion assays
All bacterial proteins were coated in PBS onto Maxisorp plates
(Nunc) overnight at 4‡C, then blocked with 3% BSA/PBS for 1 h at
37‡C. The GST^osteopontin fusion proteins GST^osteopontin amino
acid residues 17^168 (Opn17^168) and Opn153^168 were coated as
indicated, GST-CS-1 was coated at 5 Wg/ml, 100 Wl per well. The zz-
VCAM and zz-MAdCAM were adsorbed on to Maxisorp plate pre-
coated with 100 Wl of human IgG at 50 Wg/ml. For capture zz-VCAM
and zz-MAdCAM were diluted to 1 Wg/ml and 0.2 Wg/ml respectively
in 3% BSA/PBS, and incubated overnight at 4‡C. No adhesion oc-
curred to GST, BSA or IgG alone under any assay condition (data
not shown).
For the K4L7 adhesion assay RPMI8866 cells were washed in cat-
ion-free HBSS with 1 mM EDTA, pelleted and labeled with 2P,7P-
bis(2-carboxyethyl)-5(6)-carboxy£uorescein acetoxymethyl ester
(BCECF-AM) (Molecular Probes) in HBSS, 37‡C for 10 min. Fc
receptors were blocked by co-incubation with 1 Wg/ml human IgG.
After washing in cation-free HBSS, cells were used in the adhesion
assay at a ¢nal concentration of 3U106 cells ml31 in the presence of
the appropriate treatment as indicated (100 Wl per well). Assays were
performed in 50 mM HEPES pH 7.5 bu¡ered HBSS supplemented
with 2 mM MgCl2 and 50 ng/ml phorbol 12-myristate 13-acetate
(TPA) unless indicated. To prevent aggregation, plates were centri-
fuged at 400 rpm for 3 min without braking. For antibody inhibition
cells were pre-incubated with the appropriate antibody at 20 Wg/ml for
5 min at room temperature. Cells were adhered for 20 min at 37‡C,
washed twice in PBS and adhesion quantitated by BCECF £uores-
cence measurement. For the K4L1 assay Jurkat cells were pelleted,
washed once in HBSS (Sigma) then spread in 50 mM HEPES pH
7.5 HBSS with 0.2 mM MnCl2 (unless otherwise indicated) at a ¢nal
concentration of 2U106 ml31 (100 Wl per well). Cells were adhered for
35 min at 37‡C, washed twice in PBS, once in ethanol, and ¢xed in
ethanol for 20 min at room temperature. For quantitation cells were
stained with 0.1% crystal violet (Sigma) for 10 min then lysed in 0.5%
Triton X-100 (Sigma) and read at 570 nM.
3. Results
3.1. The osteopontin SVVYGLR motif supports adhesion
via K4L7
Both K4L1 and K9L1 bind to the SVVYGLR motif between
amino acid residues 162^168, terminating at the thrombin
cleavage site, Arg168 [21,22]. As K4L1 and K4L7 are related
integrins which recognise common sites in certain ligands (31)
we used RPMI8866 cells to assess whether K4L7 also binds
osteopontin. These cells express primarily K4L7, a small
amount of K4L1 and do not express any detectable Kv integ-
rins or K9L1 (data not shown).
GST^osteopontin fusion proteins support adhesion as e⁄-
ciently as puri¢ed human protein [24]. To determine the bind-
ing conditions required to support maximal binding,
RPMI8866 cells were adhered to bacterially expressed protein
mimicking thrombin cleaved osteopontin (Opn17^168) under
a range of conditions. RPMI8866 cells bound Opn17^168
maximally in Mn2 and Mg2/TPA, but only showed weak
adhesion in the presence of Mg2 alone (Fig. 1A), a pattern
that was similar to MAdCAM adhesion (Fig. 1B). The di¡er-
ence in coating concentration of ligands required to support
maximal binding is due to the di¡erent methods employed to
immobilise the ligands. Similar binding pro¢les were obtained
in the presence of function blocking anti-L1 integrin antibod-
ies indicating that the di¡erences in binding were not due to
di¡erential binding via K4L1 integrin (data not shown).
The SVVYGLR motif is the primary K4L1-binding motif in
osteopontin [21] and is proximal to the osteopontin RGD
motif, which binds Kv integrins and K5L1. To investigate
K4L7 binding to the SVVYGLR motif, RPMI8866 cells were
adhered to Opn153^168 which also contained a RGD to
RAD mutation which abrogated any interaction via RGD
dependent integrins (data not shown). The pro¢le of
RPMI8866 adhesion to Opn153^168 was similar to Opn17^
168, maximal binding occurring in Mn2 and Mg2/TPA (Fig.
1C). Jurkat cells bind the SVVYGLR motif solely through
K4L1 [21]. The pro¢le of K4L1 mediated Jurkat adhesion was
slightly di¡erent to that of K4L7, with maximal adhesion only
Fig. 1. Interaction of K4L7 with the SVVYGLR motif of osteopon-
tin. RPMI8866 were adhered to (A) Opn17^168, (B) zz-MAdCAM
and (C) Opn153^168 (SVVYGLR) in the presence of 2 mM MgCl2,
2 mM MgCl2+50 ng/ml TPA or 0.2 mM MnCl2 as indicated. Cells
were incubated at 37‡C for 20 min. D: Jurkat cells were adhered to
coated Opn153^168 (SVVYGLR), in the presence of 2 mM MgCl2,
2 mM MgCl2+50 ng/ml TPA or 0.2 mM MnCl2 as indicated at
37‡C for 30 min. E: RPMI8866 cells were adhered to Opn17^314
or Opn17^168 in the presence of 2 mM MgCl2 and 50 ng/ml TPA
at 37‡C for 20 min. F: RPMI8866 cells were adhered to Opn153^
168 in the presence or absence (control, no antibody) of anti-func-
tional integrin antibodies (20 Wg/ml), as indicated at 37‡C for 20
min in the presence of 2 mM MgCl2+50 ng/ml TPA. All the data
are representative of at least four experiments, each point represents
the mean þ S.D. of duplicate points.
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occurring the presence of Mn2, suggesting that K4L7 binds at
a lower activation state than K4L1 (Fig. 1D). Truncation of
osteopontin to Arg168 modulates the binding of RPMI8866
cells as in the presence of Mg2/TPA the full length protein
Opn17^314 bound cells poorly compared to the thrombin
cleaved fusion protein Opn17^168 (Fig. 1E). We previously
found that two sites within osteopontin could support K4L1
binding [21]. This second site, within amino acid residues 132^
146 will also support weak binding of K4L7, but only under
assay conditions that generate a maximal integrin-activation
status (data not shown). K4L1 and K4L7 integrins can therefore
access this site in the intact protein, but upon thrombin cleav-
age bind SVVYGLR motif, which is the stronger binding site
for K4 integrins.
To conclusively demonstrate that RPMI8866 bind the
SVVYGLR motif through K4L7, cells were adhered to
Opn153^168 in Mg2/TPA and with function blocking anti-
bodies (Fig. 1F). Adhesion of RPMI8866 cells to Opn153^168
was blocked by K4 and L7 integrin function blocking antibod-
ies, but not by antibodies against L1, Kv or K5 integrin, dem-
onstrating that RPMI8866 cells bind the SVVYGLR motif
exclusively via K4L7. Collectively these data establish K4L7 as
a receptor for the osteopontin SVVYGLR motif.
3.2. An SVVYGLR peptide inhibits K4L7 binding to MAdCAM
An SVVYGLR-OH peptide inhibits K4L1 binding to a GST
fusion protein corresponding to the CS-1 alternatively spliced
fragment of ¢bronectin [21]. The ability of SVVYGLR-OH
to antagonise RPMI8866 cell adhesion to MAdCAM was
assessed. RPMI8866 cells bind MAdCAM exclusively
through K4L7, as blocking antibodies against the K4 integrin
subunit and the L7 integrin subunit but not the L1 integrin
subunit blocked adhesion to zz-MAdCAM (Fig. 2A).
The SVVYGLR-OH peptide inhibited adhesion of the
RPMI8866 cells to MAdCAM, while the scrambled control
peptide had no e¡ect (Fig. 2B). That the SVVYGLR-OH
peptide antagonises the K4L7/MAdCAM interaction suggest
it is a bona ¢de ligand for K4L7. Moreover it also suggests
either that MAdCAM and osteopontin bind within the same
region of K4L7, or that binding of each ligand is mutually
exclusive.
Fig. 2. A peptide SVVYGLR inhibits K4L7 binding to MAdCAM.
A: RPMI8866 cells were adhered to zz-MAdCAM in the presence
or absence of anti-functional integrin antibodies (20 Wg/ml), as indi-
cated, at 37‡C for 20 min in the presence of 2 mM MgCl2+50 ng/
ml TPA. The data are representative of four experiments and each
data point is the mean þ S.D. of duplicate points. B: RPMI8866
cells were adhered to zz-MAdCAM in the presence of varying con-
centrations of parent SVVYGLR-OH or scrambled GRVLYSV-OH
peptides. These data are representative of at least three experiments,
and each point is the mean þ S.D. of duplicate points.
Fig. 3. The C-terminal COOH group is required for inhibition of
K4L1 and K4L7. A: Jurkat cells were adhered to GST-CS-1 in the
presence of 0.2 mM MnCl2 and (B) RPMI8866 cells were adhered
to zz-MAdCAM in the presence of 2 mM MgCl2+50 ng/ml TPA
with varying concentrations of parent SVVYGLR-OH, capped
SVVYGLR-NH2 or scrambled GRVLYSV-OH peptides. These data
are representative of at least three experiments, each point is the
mean þ S.D. of duplicate points.
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3.3. Structural elements of the SVVYGLR motif important for
the interaction with K4 integrins
As SVVYGLR-OH e¡ectively blocks adhesion of K4L1 to
CS-1 and K4L7 to MAdCAM, this approach was utilised to
determine the structural elements of the SVVYGLR motif
that interact with K4L1 and K4L7. A number of the K4 integrin
motifs contain a critical acidic residue, normally an Asp [24^
29,31,32]. One signi¢cant feature of the SVVYGLR motif is
that it lacks an obvious acidic group, therefore understanding
how this motif binds K4 integrins could have important im-
plications for the design of small molecule antagonists. The
SVVYGLR site is located immediately N-terminal to the
thrombin cleavage site, Arg168, with truncation of osteopon-
tin at Arg168 modulating the interaction with both K4L1 and
K9L1 [21,22]. It is possible that cleavage at Arg168 reveals a
carboxylic acidic group, enabling the SVVYGLR motif to
engage K4 integrins. To test this hypothesis a capped carbox-
amide peptide SVVYGLR-NH2 was synthesised and assayed
for the ability to inhibit Jurkat and RPMI8866 cell adhesion
to GST-CS-1 and zz-MAdCAM respectively (Fig. 3A,B). Re-
moving the carboxylic acid group at the free C-terminus ab-
rogated the ability of this peptide to inhibit adhesion via both
K4L1 and K4L7. Therefore the free C-terminus of SVVYGLR
provides an acidic group essential for its interaction with K4
integrins. Moreover this data suggest thrombin cleavage of
osteopontin at Arg168 is required for K4L1 and K4L7-depen-
dent ligation of the SVVYGLR motif.
To further determine which other elements of the
SVVYGLR motif are required for the interaction with K4
integrins, a series of synthetic peptides were generated in
which each amino acid was individually mutated to alanine.
The ability of each peptide to block adhesion of Jurkat and
RPMI8866 cells to GST-CS-1 and zz-MAdCAM respectively
was then assayed. The activity of each peptide is shown in
Fig. 4 expressed as a relative potency (RP) compared to the
activity of the parent peptide SVVYGLR-OH. This analysis
clearly shows that Leu167 is also important. Mutating this
residue results in a RP similar to that observed with the
capped peptide SVVYGLR-NH2 or the scrambled control.
A number of other residues also make a minor contribution
to binding in particular Val163 and Tyr165. Mutation of these
residues reduced the potency against both integrins. The ob-
servation that Tyr165 makes only a minor contribution to K4
binding is interesting as this residue appears to be critical for
the interaction with K9L1 [22]. Surprisingly mutation of
Arg168 has opposite e¡ects on the potency of the peptide
against K4L1 and K4L7. Mutating this residue to Ala results
in a peptide that is more potent against K4L1 but less potent
against K4L7. Therefore the residue at this position may confer
some selectivity between K4L1 and K4L7. Collectively these
data show that Leu167 and the C-terminal carboxylic acid
of Arg168 are the most critical elements within the
SVVYGLR motif for binding to K4 integrins. These data
are summarised in Fig. 4B.
4. Discussion
Here we have shown that in addition to K4L1 and K9L1 the
related integrin K4L7 also binds osteopontin through the
SVVYGLR motif. The SVVYGLR-OH peptide acts as an
K4L7 antagonist capable of inhibiting K4L7 adhesion to MAd-
CAM, demonstrating that this motif binds with su⁄cient af-
¢nity to compete with known K4L7 ligands.
Importantly the SVVYGLR peptide requires the free C-ter-
minal carboxylic acid of Arg168 to interact with K4 integrins,
as a peptide SVVYGLR-NH2 in which the carboxylic acid
was replaced with a carboxamide failed to inhibit cell adhe-
sion mediated by either K4L1 or K4L7. This suggests that in
vivo osteopontin must be cleaved by thrombin at Arg168 to
enable K4 integrins to engage this motif, this is supported by
the observation that truncation of osteopontin to Arg168
modulates the interaction with K4L7 and also K4L1 [21].
Moreover, like the classical K4 integrin-binding sites,
SVVYGLR requires a critical acidic moiety. This is provided
by Asp in motifs such as LDVP, l/LDAP, or IDSP found in
[24^27,31,32] as well as the disintegrin EC3 [28,29]. The data
presented here raise the novel suggestion that the critical
acidic group can also be provided by the free C-terminus of
a protein fragment generated by proteolytic cleavage.
The inhibition studies using a series of Ala-substituted pep-
Fig. 4. Identi¢cation of key residues within SVVYGLR required for
inhibition of K4L1 and K4L7. A: Jurkat (black bars) and RPMI8866
cells (grey bars) were adhered to CS-1 and zz-MAdCAM in 0.2
mM MnCl2 and 2 mM MgCl2+50 ng/ml TPA respectively and a
series of individual alanine-substituted SVVYGLR-OH based pep-
tides. The data are expressed as a RP compared to the IC50 of par-
ent peptide SVVYGLR-OH in each individual experiment
(RP = (IC50 of mutant peptide)/(IC50 of SVVYGLR-OH) s 1 = less
active and 6 1 = more active than the parent peptide), and repre-
sents the mean of four experiments þ S.E.M. (*P9 0.05;
**P9 0.001). B: Summary of the key elements of the SVVYGLR
motif.
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tides revealed that Leu167 is also important for the interac-
tion with K4 integrins. A number of other residues make mi-
nor contributions, in particular mutating Val163 and Tyr165
reduces the ability of the peptide to block both K4L1 and K4L7.
Yokosaki et al. [22] showed that Tyr165 was critical for os-
teopontin to bind K9L1, raising the possibility that although
K4 integrins and K9L1 bind similar motifs in common ligands,
the importance of individual residues may di¡er between the
integrins. Mutating Arg168 to Ala increased the activity
against K4L1 but reduced the activity against K4L7, suggesting
that peptides with selectivity between receptors could be gen-
erated.
It has been suggested that ligands occupy di¡erent regions
of K9L1 as SVVYGLR only inhibits K9L1-mediated adhesion
to osteopontin, but not VCAM or tenascin. Our data suggest
that for K4L7 SVVYGLR can occupy a binding site similar to
that for MAdCAM and for K4L1 similar to CS-1. However
SVVYGLR will only partially inhibit K4L1 binding to VCAM,
and does not block K4L7 binding (data not shown), whether
this re£ects occupancy of di¡erent binding sites or the a⁄nity
of the peptide is unclear.
The interaction between K4 integrins and osteopontin is
highly regulated. Not only does the SVVYGLR motif require
activation by thrombin, but neither K4L1 or K4L7 bind osteo-
pontin unless the integrin is ‘activation’. K4L7 exhibits max-
imal binding in the presence of Mn2 or Mg2/TPA, while
K4L1 only binds maximally in Mn2, and binds sub-maximally
in Mg2/TPA. These conditions are thought to stimulate the
activation state of the integrin, This would suggest that osteo-
pontin is only engaged by K4 integrins when cells are stimu-
lated in a proteolytic environment, for example during an
in£ammatory response. In vivo the interactions of K4L1 are
highly regulated, as K4L1 can occupy a variety of activation
states [33,34]. This basal activation state di¡ers between cell
types and is rapidly altered by various cytokines. This sug-
gests that the interaction of K4L1 and K4L7 with osteopontin is
not one primarily involved in mediating cell transmigration
from the vasculature but may ful¢l some other function
such as eliciting K4-dependent responses in a target tissue or
mediating cell migration.
Acknowledgements: We thank Julia Ticehurst for advice and technical
assistance, and Peter Seale, Corinne Kay and Carla Smith for peptide
synthesis.
References
[1] Hynes, R.O. (1992) Cell 69, 11^25.
[2] Clark, E.A. and Brugge, J.S. (1995) Science 268, 233^239.
[3] Palmer, E.L., Ruegg, C., Ferando, R., Pytela, R. and Sheppard,
D. (1993) J. Cell Biol. 123, 1289^1297.
[4] Lobb, R.R. and Hemler, M.E. (1994) J. Clin. Invest. 94, 1722^
1728.
[5] Springer, T.A. (1994) Cell 76, 301^314.
[6] Carlos, T.M. and Harlan, J.M. (1994) Blood 84, 2068^2101.
[7] Ruegg, C., Postigo, A.A., Sikorski, E.E., Butcher, E.C., Pytela,
R. and Erle, D.J. (1992) J. Cell Biol. 117, 179^189.
[8] Taooka, Y., Chen, J., Yednock, T. and Sheppard, D. (1999)
J. Cell Biol. 145, 413^420.
[9] Alon, R., Kassner, P.D., Carr, M.W., Finger, E.B., Hemler,
M.E. and Springer, T.A. (1995) J. Cell Biol. 128, 1243^1253.
[10] Berlin, C., Bargatze, R.F., Campbell, J.J., von Andrian, U.H.,
Szabo, M.C., Hasslen, S.R., Nelson, R.D., Berg, E.L., Erlandsen,
S.L. and Butcher, E.C. (1995) Cell 80, 413^422.
[11] Bochner, B.S., Luscinskas, F.W., Gimbrone, M.A.Jr., Newman,
W., Sterbinsky, S.A., Derse-Anthony, C.P., Klunk, D. and
Schleimer, R.P. (1991) J. Exp. Med. 173, 1553^1556.
[12] Wahl, S.M., Allen, J.B., Hines, K.L., Imamichi, T., Wahl, A.M.,
Furcht, L.T. and McCarthy, J.B. (1994) J. Clin. Invest. 94, 655^
662.
[13] Molossi, S., Elices, M., Arrhenius, T., Diaz, R., Coulber, C. and
Rabinovitch, M. (1995) J. Clin. Invest. 95, 2601^2610.
[14] Shih, P.T., Brennan, M.L., Vora, D.K., Territo, M.C., Strahl, D.,
Elices, M.J., Lusis, A.J. and Berliner, J.A. (1999) Circ. Res. 84,
345^351.
[15] Miyauchi, A., Alvarez, J., Green¢eld, E.M., Teti, A., Grano, M.,
Colucci, S., Zambonin-Zallone, A., Ross, F.P., Teitelbaum, S.L.
and Cheresh, D. et al. (1991) J. Biol. Chem. 266, 20369^20374.
[16] Ross, F.P., Chappel, J., Alvarez, J.I., Sander, D., Butler, W.T.,
Farach-Carson, M.C., Mintz, K.A., Robey, P.G., Teitelbaum,
S.L. and Cheresh, D.A. (1993) J. Biol. Chem. 268, 9901^9907.
[17] Liaw, L., Almeida, M., Hart, C.E., Schwartz, S.M. and Giachelli,
C.M. (1994) Circ. Res. 74, 214^224.
[18] Hu, D.D., Hoyer, J.R. and Smith, J.W. (1995) J. Biol. Chem.
270, 9917^9925.
[19] Hu, D.D., Lin, E.C., Kovach, N.L., Hoyer, J.R. and Smith, J.W.
(1995) J. Biol. Chem. 270, 26232^26238.
[20] Denda, S., Reichardt, L.F. and Muller, U. (1998) Mol. Biol. Cell
9, 1425^1435.
[21] Barry, S.T., Ludbrook, S.B., Murrison, E. and Horgan, C.M.T.
(2000) Exp. Cell Res. 258, 342^351.
[22] Yokosaki, Y., Matsuura, N., Sasaki, T., Murakami, I.,
Schneider, H., Higashiyama, S., Saitoh, Y., Yamakido, M.,
Taooka, Y. and Sheppard, D. (1999) J. Biol. Chem. 274,
36328^36334.
[23] Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S.,
Hemler, M.E. and Lobb, R.R. (1990) Cell 60, 577^584.
[24] Newham, P., Craig, S.E., Seddon, G.N., Scho¢eld, N.R., Rees,
A., Edwards, R.M., Jones, E.Y. and Humphries, M.J. (1997)
J. Biol. Chem. 272, 19429^19440.
[25] Guan, J.L. and Hynes, R.O. (1990) Cell 60, 53^61.
[26] Mould, A.P. and Humphries, M.J. (1991) EMBO J. 10, 4089^
4095.
[27] Moyano, J.V., Carnemolla, B., Dominguez-Jimenez, C., Garcia-
Gila, M., Albar, J.P., Sanchez-Aparicio, P., Leprini, A., Querze,
G., Zardi, L. and Garcia-Pardo, A. (1997) J. Biol. Chem. 272,
24832^24836.
[28] Marcinkiewicz, C., Calvete, J.J., Marcinkiewicz, M.M., Raida,
M., Vijay-Kumar, S., Huang, Z., Lobb, R.R. and Niewiarowski,
S. (1999) J. Biol. Chem. 274, 12468^12473.
[29] Marcinkiewicz, C., Taooka, Y., Yokosaki, Y., Calvete, J.J., Mar-
cinkiewicz, M.M., Lobb, R.R., Niewiarowski, S. and Sheppard,
D. (2000) J. Biol. Chem. 275, 31930^31937.
[30] Yokosaki, Y., Matsuura, N., Higashiyama, S., Murakami, I.,
Obara, M., Yamakido, M., Shigeto, N., Chen, J. and Sheppard,
D. (1998) J. Biol. Chem. 273, 11423^11428.
[31] Chan, B.M., Elices, M.J., Murphy, E. and Hemler, M.E. (1992)
J. Biol Chem. 267, 8366^8370.
[32] Berlin, C., Berg, E.L., Briskin, M.J., Andrew, D.P., Kilshaw,
P.J., Holzmann, B., Weissman, I.L., Hamann, A. and Butcher,
E.C. (1993) Cell 74, 185^195.
[33] Masumoto, A. and Hemler, M.E. (1993) J. Biol. Chem. 268, 228^
234.
[34] Chen, L.L., Whitty, A., Lobb, R.R., Adams, S.P. and Pepinsky,
R.B. (1999) J. Biol. Chem. 274, 13167^13175.
FEBS 25099 6-8-01
P.M. Green et al./FEBS Letters 503 (2001) 75^79 79
